Table 2.
Treatment Characteristics for 40 Patients
| Treatment Characteristics | No. (%) |
|---|---|
| Total no. of cycles | 363 |
| Median no. of cycles per patient [range] | |
| Chemotherapy+bevacizumab | 6 [1–6] |
| Maintenance bevacizumab | 2 [0–40] |
| Patients with carboplatin dose reductions | |
| No dose reductions | 35 (88) |
| 1 Level (carboplatin AUC 5) | 5 (13) |
| 2 Levels (carboplatin AUC 4) | 0 |
| Patients with docetaxel dose reductions | |
| No dose reductions | 34 (85) |
| 1 Level (docetaxel 60 mg/m2) | 6 (15) |
| 2 Levels (docetaxel 50 mg/m2) | 0 |
| Median time on treatment, wka | 21 |
| Patients who discontinued treatment because of | |
| Disease progression | 20 (50) |
| Toxicities | 12 (30) |
| Achieved maximal benefit | 1 (3) |
| Need for radiotherapy | 1 (3) |
| Death | 1 (3) |
| Still on study | 5 (13) |
AUC indicates area under curve.
a
Calculated from the date of the first chemotherapy administration until the date of the last chemotherapy administration on study.